A retrospective study of Yiqibushenhuoxue decoction for the treatment of chronic obstructive pulmonary disease

Citation metadata

Date: Aug. 2018
From: Medicine(Vol. 97, Issue 31)
Publisher: Lippincott Williams & Wilkins, WK Health
Document Type: Author abstract; Report
Length: 357 words

Document controls

Main content

Abstract :

Byline: Zhuying Li, Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang University of Chinese Medicine, The Key Laboratory of Ministry of Education in North Medicine Basic and Applied Research, Heilongjiang University of Chinese Medicine; Chunyan Tian, Heilongjiang University of Chinese Medicine; Xuehui Wang, Department of Respiratory Medicine, First Affiliated Hospital of Heilongjiang University of Chinese Medicine, Heilongjiang University of Chinese Medicine, The Key Laboratory of Ministry of Education in North Medicine Basic and Applied Research, Heilongjiang University of Chinese Medicine; Liqin Wang, Department of First clinical medicine, Heilongjiang University of Chinese Medicine, Harbin, China. Abstract This retrospective study aimed to investigate the effect and safety of Yiqibushenhuoxue decoction (YQBSHXD) for the treatment of chronic obstructive pulmonary disease (COPD).This study involved 120 cases of patients with COPD. These cases were assigned to an intervention group and a control group equally, 60 subjects each group. Patients in both groups underwent Salmeterol. In addition, the cases in the intervention group also received YQBSHXD. All cases received a total of 12 weeks treatment. The primary outcome of lung function was measured by forced expiratory volume in 1 second (FEV1), and FEV1/forced vital capacity (FVC). The secondary outcomes included severity of dyspnea on exertion, evaluated by 6-minute walk test (6MWT) with measurement of 6-minute walk distance (6MWD); and quality of life, assessed by the St. George's Respiratory Questionnaire (SGRQ). In addition, adverse events (AEs) were also recorded in this study. All outcome measurements were assessed before and after 12-week treatment.After 12-week treatment, cases in the intervention group underwent YQBSHXD did not show better outcome in lung function improvement, measured by the FEV1 (P = .11), and FEV1/FVC (P = .15), compared with those in the control group. However, YQBSHXD may help to alleviate the severity of dyspnea on exertion, as measured by 6MWD (P = .03), and to improve the quality of life, as assessed by the SGRQ (P

Source Citation

Source Citation   

Gale Document Number: GALE|A548715652